345 related articles for article (PubMed ID: 36002104)
21. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients].
Guan FS; He DH; Li Y; Zhang Y; Zheng GF; Zhu YY; He JS; Zhang EF; Cai Z; Zhao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1056-1060. PubMed ID: 37551477
[TBL] [Abstract][Full Text] [Related]
22. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
23. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.
Tolomelli G; Mancuso K; Tacchetti P; Patriarca F; Galli M; Pantani L; Zannetti B; Motta MR; Rizzi S; Dan E; Sinigaglia B; Giudice V; Olmo A; Arpinati M; Chirumbolo G; Fanin R; Lewis RE; Paris L; Bonifazi F; Cavo M; Curti A; Lemoli RM
Bone Marrow Transplant; 2020 May; 55(5):946-954. PubMed ID: 31768009
[TBL] [Abstract][Full Text] [Related]
24. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
26. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
27. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
Zhuang L; Lauro D; Wang S; Yuan S
J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
[TBL] [Abstract][Full Text] [Related]
28. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
29. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
[TBL] [Abstract][Full Text] [Related]
31. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
32. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
33. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K; Fresen MM; Salwender H; Basara N; Beier R; Theurich S; Christopeit M; Bogner C; Galm O; Hartwig R; Heits F; Lordick F; Rösler W; Wehler D; Zander AR; Albert MH; Dressler S; Ebinger M; Frickhofen N; Hertenstein B; Kiehl M; Liebler S; von Lilienfeld-Toal M; Weidmann E; Weigelt C; Lange F; Kröger N
Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N
Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
[TBL] [Abstract][Full Text] [Related]
35. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
36. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
37. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
38. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
39. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
[TBL] [Abstract][Full Text] [Related]
40. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
Shi PA; Miller LK; Isola LM
Transfusion; 2014 May; 54(5):1263-8. PubMed ID: 24128272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
